Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts

• Type of Material: Article
• Authors: Dedee F. Murrell, University of New South Wales; Benjamin S. Daniel, University of New South Wales; Pascal Joly, University of Rouen; Luca Borradori, University Hospital of Bern; Masayuki Amagai, Keio University; Takashi Hashimoto, Kurume University; Frederic Caux, University of Paris XIII; Branka Marinovic, University of Zagreb; Animesh A. Sinha, State University of New York at Buffalo; Michael Hertl, University Hospital, Marburg; Philippe Bernard, Robert Debre University Hospital; David Sirois, New York University; Giuseppe Cianchini, stituto Di Ricovero e Cura a Carattere Scientifico; Janet A. Fairley, University of Iowa; Marcel F. Jonkman, University of Groningen; Amit G. Pandya, University of Texas Southwestern Medical Center Dallas; David Rubenstein, University of North Carolina; Detlef Zillikens, University of Lubeck; Aimee S. Payne, University of Pennsylvania; Robert Swerlick, Emory University
• Language: English
• Date: 2012-03-01
• Publisher: Elsevier: 12 months
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2011 by the American Academy of Dermatology, Inc.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.jaad.2011.06.032
• Title of Journal or Parent Work: Journal of The American Academy of Dermatology
• ISSN: 0190-9622
• Volume: 66
• Issue: 3
• Start Page: 479
• End Page: 485
• Grant/Funding Information: This report was supported in part by a grant from the National Institutes of Health (K24-AR 02207) to Dr Werth.; The International Pemphigus and Pemphigoid Foundation generously supported renting rooms at the American Academy of Dermatology and audiovisual equipment; the European Society for Dermatological Research and European Academy of Dermatology provided meeting rooms.
• Keywords: TOPICAL CORTICOSTEROIDS; Dermatology; consensus; outcome measures; definitions; Life Sciences & Biomedicine; severity score; bullous pemphigoid; Science & Technology
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies.